CHICAGO – Biosensor provider PhysIQ has received clearance from the U.S. Food and Drug Administration for its atrial fibrillation detection analytics engine. “Since day one, our mission has been to enable a world where real-time patient data continuously streams to the cloud and artificial intelligence performs the hard work of detecting when health problems are arising among monitored patients,” said Gary Conkright, chairman and CEO of PhysIQ, in a statement. “With this approach, clinicians can identify who within their monitored population may require additional care to avoid poor health outcomes. This clearance of our AFib detection algorithm, when paired with our groundbreaking and previously cleared personalized physiology analytics, is a huge step toward realizing that goal.” The AFib analytic will be available within PhysIQ’s pinpointIQ monitoring solution, which combines clinical-grade wearable biosensors, mobile cloud computing and FDA-cleared analytics to provide clinicians with continuous insight for at-risk patients. The solution is currently being used by payers and providers to better care for patients recently discharged from the hospital, recovering at a skilled nursing facility or enrolled in a home health program. The AFib analytic is also available to pharma and medical device companies that are integrating wearable biosensors into their clinical trials.
You are here: / / FDA clears PhysIQ’s Afib analytics engine